Celladon says heart treatment fails in trial
Sunday, April 26, 2015 - 17:30
in Health & Medicine
NEW YORK (Reuters) - Celladon Corp said its heart failure gene therapy Mydicar failed to meet its primary and secondary endpoints in an important trial.